Development of a validated LC-MS/MS method for the in vitro and in vivo quantitation of sunitinib in glioblastoma cells and cancer patients
- 1 February 2019
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 164, 690-697
Abstract
No abstract availableKeywords
Funding Information
- Blood Donation Center of the University Hospital of Ioannina
This publication has 57 references indexed in Scilit:
- Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasmsJournal of Cancer Research and Clinical Oncology, 2018
- Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanomaCancer, 2015
- Sunitinib administered prior to radiotherapy in patients with non-resectable glioblastoma: results of a Phase II studyTargeted Oncology, 2014
- Early Monitoring Antiangiogenesis Treatment Response of Sunitinib in U87MG Tumor Xenograft by18F-FLT MicroPET/CT ImagingBioMed Research International, 2014
- The potential of sunitinib as a therapy in ovarian cancerExpert Opinion on Investigational Drugs, 2013
- Mechanisms of Glioma-Associated NeovascularizationThe American Journal of Pathology, 2012
- Clinical Pharmacokinetics of Tyrosine Kinase InhibitorsClinical Pharmacokinetics, 2011
- MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinibNeuro-Oncology, 2010
- SunitinibBioDrugs, 2009
- Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastomaNeuro-Oncology, 2007